Deltex Medical (LON:DEMG) summed up the outcome of the first half as “substantial progress” and said that the cash break-even point was likely to come before the end of the current year.
The roll-out of Deltex’s key product, the CardioQ-ODM system, is expected to be aided by the new NHS quality and efficiency programmes that are currently being introduced.
Investors agreed with the company’s upbeat assessment of its prospects, triggering a buying spree that sent shares up 12.5% in early afternoon deals.
Sales jumped 13% to £2.9 million, while operations expenses decreased 7% to £2.8 million and operating losses were slashed nearly in half to £0.6 million. Gross margins were up 1%.
Gross profit climbed from £1.9 million to £2.2 million, while pre-tax losses declined from £1.2 million to £0.6 million.
The increase in revenues was driven by a significant improvement in probe sales in key target markets. US sales jumped 35%, while sales to European distributors soared 39%. UK surgical probe sales rose 16%, leading to an overall increase of 4%.
Deltex’s largest US account agreed to buy at least 200 probes every month worth the minimum of US$34,000.
“We are pursuing a number of new opportunities for such structured implementation projects in influential hospitals,” said chairman of Deltex Medical Nigel Keen.
Overall, the probe sales accounted for two thirds of the total revenue increase.
Higher sales at better margins on a reduced cost base led to lower cash expenses. The company is currently on track to pass the cash break-even point in the second half with only modest further sales growth.
“Deltex Medical made substantial progress in the first half of 2010 with sales growth rates continuing to recover from the global recession, with the strongest probe sales growth coming from our key markets.
“Deltex Medical is building a solid base from which to create shareholder value over a prolonged period,” said Keen.
The company added that due to its clinical and cost effectiveness, it is positioned to “create and exploit opportunities for accelerated growth” with health systems increasingly focusing on improving outcomes and reducing costs.
Deltex’s main product it the CardioQ-ODM (oesophageal Doppler monitoring) system comprising a monitor and a single patient disposable probe.
A recently published Department of Health guide highlighted the pivotal role of intra-operative fluid management and ODM in enhancing recovery after surgery.
A number of hospitals and regions have started the planning required to implement enhanced recovery programmes in the coming months and the company expects introduction of these programmes to lead to increased probe sales.
Back in January, the NHS National Technology Adoption Centre published a guide on how to procure and implement ODM into routine practice based on its experiences working with three NHS hospitals.
The company has noted that number of localised initiatives to use this guide as a template to expand use of CardioQ-ODM in England and two Strategic Health Authorities have awarded grants to hospitals specifically to support this activity.
The Medical Technologies Advisory Committee, which was set up by The National Institute for Health and Clinical Excellence (NICE), has selected CardioQ-ODM for early review and is scheduled to publish final guidance by early 2011, with draft guidance expected within weeks.